Cystic Fibrosis Financial Planning: Trikafta Costs, SSDI Strategy, and the Medicaid Preservation Problem

CFTR modulators have transformed cystic fibrosis from a disease with a median survival of roughly 30 years into one where a person starting Trikafta between ages 12 and 17 may live to a near-normal lifespan. That is an extraordinary medical achievement — and it creates an equally extraordinary financial planning problem. The drug that enables this outcome costs approximately $370,000 per year at wholesale. For the roughly 40,000 Americans with CF, insurance continuity is not a background concern; it is the central financial risk in their plan. This guide covers what financial planning for CF requires beyond what a general advisor understands: how to preserve Medicaid access while working, when and how to qualify for SSDI, how to structure a Special Needs Trust for a planning horizon that may now span 50 or more years, and what lung transplant planning looks like for families who face that path.

Why CF financial planning is different

Cystic fibrosis creates a financial planning profile that differs from most other conditions on this site in three ways that reshape the planning approach:

• The dominant annual cost is a single drug, not care services. For conditions like spinal cord injury or cerebral palsy, the biggest ongoing expenses are personal care attendants, equipment, and housing supports. For CF, the dominant cost is the CFTR modulator — Trikafta or Alyftrek — at approximately $370,000 per year wholesale. The entire financial plan must be designed around insurance continuity: making sure this coverage never lapses, through every job change, every income transition, and the eventual shift from employer insurance to Medicare or Medicaid.
• Most CF adults work — and the modulator has made this increasingly true. Before CFTR modulators, many CF adults could not sustain full employment due to pulmonary decline and frequent hospitalization. On Trikafta, significant numbers of CF adults now maintain professional careers, marry, buy homes, and have children. This is different from most conditions seen by special needs financial planners, where lifetime employment is the exception. CF financial planning must address SSI/Medicaid preservation for working adults at multiple income levels — not just the low-income scenario.
• The planning horizon has extended dramatically — and is now uncertain. A CF adult born in the 1980s was planning for a lifespan of perhaps 40 years. The same person on Trikafta today may have a near-normal life expectancy. Parents setting up a Special Needs Trust for a CF child in 2026 are planning for a 50–70 year trust duration, funded by assets that must also last through the parents' retirement. The math is fundamentally different — and requires a specialist advisor who understands how to model SNT funding for a near-normal lifespan when the primary beneficiary also has a $370,000/year medication cost.

The CFTR modulator landscape: cost context

Understanding what CFTR modulators cost — and how they are paid for — is prerequisite to any CF financial plan.

Trikafta and Alyftrek pricing

Trikafta (elexacaftor/tezacaftor/ivacaftor), FDA-approved in 2019 and expanded to patients as young as 2 years old by 2023, carries a wholesale acquisition cost of approximately $370,000 per year.¹ Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), the next-generation once-daily triple combination approved by the FDA in late 2024, carries the same wholesale acquisition cost of $370,269 per year.² Both drugs are manufactured by Vertex Pharmaceuticals. Alyftrek offers a once-daily dosing schedule (versus Trikafta's twice-daily regimen) for patients aged 6 and older who carry at least one responsive mutation.

Actual out-of-pocket costs for commercially insured patients are dramatically lower than the list price — Vertex's patient assistance programs reduce co-pays to $0 for many patients with commercial insurance, with a maximum savings cap of approximately $20,000 per year. Medicaid covers both drugs with prior authorization in most states. Medicare Part D covers them, subject to the 2026 $2,100 annual out-of-pocket cap under the Inflation Reduction Act's Part D redesign.

The risk is not what patients pay when covered. The risk is coverage gaps: job loss, income exceeding Medicaid eligibility thresholds, COBRA lapse, a change in employer health plan formulary, or reaching Medicare Part D before Medicaid wraps around the gap. A financial plan that doesn't explicitly model these scenarios is not an adequate CF financial plan.

What coverage actually pays for

Medicaid: the foundation of CF financial planning

For CF adults who are not employed with robust employer insurance, Medicaid is the financial foundation that makes CFTR modulator treatment economically viable. Understanding Medicaid eligibility rules, and how to preserve access while working, is the single most important piece of CF financial planning for adults at any income level.

SSI-linked Medicaid

CF adults who receive SSI receive Medicaid automatically in most states (and may also receive it through separate Medicaid eligibility rules). SSI's countable resource limit of $2,000 means that any inheritance, settlement, or substantial gift received directly will end SSI and Medicaid eligibility — the same rule that applies to all special needs beneficiaries. See the First-Party vs Third-Party SNT guide for how trust structures protect SSI and Medicaid while allowing the CF adult to benefit from inherited or gifted assets.

Section 1619(b): Medicaid protection when earnings rise

Section 1619(b) of the Social Security Act allows an SSI recipient to continue receiving Medicaid after earned income exceeds the SSI payment level, provided the person:³

• Remains enrolled in SSI (even if the monthly SSI payment is reduced to $0 by earnings)
• Has earnings below the state's individual 1619(b) threshold (varies by state — typically $25,000–$65,000/year; higher in states with expensive Medicaid services)
• Would be unable to afford equivalent Medicaid replacement through private insurance

For a CF adult earning $45,000/year and relying on Medicaid for a $370,000/year drug, the 1619(b) threshold means they may retain Medicaid even at incomes far above the SSI eligibility level. This protection is not automatic — the person must remain enrolled in SSI, file appropriate reports, and confirm 1619(b) status with their state agency. A lapse in SSI enrollment can end 1619(b) protection and trigger a full Medicaid redetermination.

Medicaid waiver for more disabled CF adults

CF adults with more severe pulmonary impairment or frequent exacerbations may qualify for a physical disability HCBS (Home and Community-Based Services) Medicaid waiver, which covers personal care attendant hours for activities of daily living that CF pulmonary decline can affect. The same waitlist urgency applies here as with other physical disabilities: apply early, as waitlists range from 1 to 5+ years in many states. See the HCBS Medicaid Waiver guide for enrollment strategy.

SSDI qualification: SSA Blue Book Listing 3.04

CF adults who can no longer work — due to pulmonary decline, frequent hospitalizations, or post-transplant complications — may qualify for Social Security Disability Insurance. The relevant listing is 3.04 (Cystic Fibrosis) in the SSA's Blue Book respiratory section.⁴

The six Listing 3.04 pathways

The FEV1-based Pathway A is typically the most relevant for progressive CF. However, Trikafta has substantially improved FEV1 for many CF patients — meaning some adults who might previously have met Listing 3.04A may now have FEV1 values above the table threshold. If the listing is not met on lung function alone, Pathways B through F still apply, and SSA also evaluates residual functional capacity (RFC) — a holistic assessment of what the person can and cannot do — when listing criteria are not met outright. A CF adult who does not meet 3.04A but has frequent exacerbations, fatigue, or CF-related diabetes, liver disease, or malnutrition may still qualify through RFC.

The SSDI transition: timing and the Medicare gap

For CF adults who transition from employment to disability, the financial planning challenge has two stages: (1) the decision of when to apply for SSDI, and (2) bridging the 24-month Medicare waiting period without losing CFTR modulator coverage.

SSDI timing considerations

Applying too early — when there is still meaningful work capacity — forecloses earnings and may result in a denied claim. Applying too late — when pulmonary decline has progressed significantly — means years of lower-than-necessary income leading up to the application and reduced SSDI benefit if earned income was falling. The optimal SSDI timing is generally when the CF adult can no longer reliably sustain substantial gainful activity ($1,690/month in 2026 for non-blind individuals).³ A specialist advisor familiar with CF disease trajectory should be involved in this analysis before the application is filed.

The Medicare gap and COBRA bridge

SSDI entitlement triggers a mandatory 5-month waiting period, then a 24-month waiting period before Medicare begins — 29 months total from the disability onset date. For a CF adult transitioning off employer insurance, the primary bridge options are:

• COBRA with the disability extension. When SSA determines the disability existed at the time the qualifying event occurred (job loss or reduction in hours), the standard 18-month COBRA period extends to 29 months. This aligns precisely with the Medicare waiting period for SSDI. The full COBRA premium — often $700–$1,500+/month for individual coverage — must be paid, but Vertex's Trikafta/Alyftrek copay assistance programs typically continue on COBRA plans.
• ACA Marketplace plan. ACA plans cover Trikafta/Alyftrek (insurers cannot deny based on pre-existing conditions), and Advanced Premium Tax Credits reduce premiums for those with income below 400% of the federal poverty level. If the CF adult has little income during the SSDI waiting period, an ACA plan with robust drug coverage may be cheaper than COBRA.
• Medicaid. If the CF adult has low income during the SSDI gap, state Medicaid expansion covers them and provides drug coverage. This is the cleanest bridge for low-income applicants. The 1619(b) rules from SSI enrollment (if applicable) may also provide Medicaid continuity.

Do not leave CFTR modulator coverage to chance during the SSDI transition. A financial model of the Medicare gap should be part of every CF adult's disability planning, run several years before SSDI becomes likely — not at the time of crisis.

Life insurance and long-term disability strategy

The life insurance and disability insurance picture for CF changed substantially with CFTR modulators. The planning window exists — and it narrows as disease progresses.

Life insurance for CF adults

Prior to CFTR modulators, most life insurance underwriters declined CF applicants or issued policies with rated premiums that reflected severely shortened life expectancy. That landscape is shifting. Some insurers now issue life insurance policies to CF adults who have been on Trikafta or Alyftrek for 12 or more months, with stable or improving FEV1 and no recent exacerbations. Coverage is not universal — underwriting decisions vary by carrier — but coverage at standard or near-standard rates has become possible for some well-controlled CF adults.

For CF adults who can obtain life insurance, purchasing it while health is well-controlled is critical. If pulmonary function declines — or if the person is listed for lung transplant — obtaining individual life insurance coverage typically becomes impossible. Work with an independent life insurance broker experienced in high-risk or impaired-risk underwriting who can shop policies across multiple carriers simultaneously rather than presenting the case to one insurer at a time.

For parents wanting to fund a Special Needs Trust for a CF child, the discussion is different: parents need life insurance on themselves, and this is generally straightforward as long as the parents themselves are in good health. The insured life in a life-insurance-funded SNT is the parent, not the CF child. See the Life Insurance for Special Needs Trusts guide for the survivorship policy strategy and beneficiary designation mechanics.

Long-term disability insurance

Long-term disability (LTD) insurance replaces a portion of earned income when the CF adult cannot work. Group LTD through an employer is the most accessible entry point for CF adults, since group policies typically offer enrollment without individual underwriting. If an employer offers LTD, a CF adult should maximize coverage — including any optional supplemental LTD elections that do not require medical underwriting — as early in employment as possible, before any waiting periods or evidence-of-insurability requirements arise.

Individual LTD policies are increasingly difficult for CF adults to obtain at standard rates, though this too is evolving as underwriters assess outcomes on CFTR modulators. The critical timing: purchase LTD coverage while employed and healthy, before pulmonary decline makes individual coverage unavailable. A CF adult who waits until significant disease progression cannot retrospectively purchase the income protection they need during the working years.

Own-occupation LTD coverage — which pays when the person cannot perform their specific occupation, rather than any job — is worth purchasing over any-occupation coverage if available. CF-related fatigue, frequent medical appointments, and pulmonary decline may prevent a professional CF adult from maintaining their demanding career while still technically being able to do some kind of work. Own-occupation coverage provides the more protective standard.

Special Needs Trust strategy for CF families

The SNT structure for CF families depends on whose assets are being protected and whether the CF individual is on SSI/Medicaid.

Third-party SNT: parents and family members planning for a CF beneficiary

A third-party SNT allows parents, grandparents, and siblings to leave assets for a CF family member without destroying their SSI and Medicaid eligibility. A direct bequest, beneficiary designation, or substantial gift to a CF individual on SSI immediately counts as a resource and ends benefits once the $2,000 countable resource limit is exceeded. A third-party SNT holds the inherited or gifted assets for the CF beneficiary's benefit while preserving SSI and Medicaid.

For CF families in 2026, the critical point is the planning horizon. With Trikafta extending life expectancy toward near-normal, a third-party SNT established by parents who are currently in their 50s may need to fund supplemental care for 50 or more additional years. The SNT should be sized accordingly — factoring in:

• Drug cost volatility: even though Medicaid or Medicare typically covers Trikafta/Alyftrek, policy changes, Medicaid reform, or future drug iterations may shift out-of-pocket costs. An SNT reserve for drug coverage lapses is prudent planning.
• Supplemental medical costs not covered by Medicaid: dental (usually limited or excluded from Medicaid), vision, CF-related mental health services (anxiety and depression are significantly elevated in the CF population), and complementary therapies.
• Lung transplant scenario: if a bilateral lung transplant occurs, the SNT can fund co-pays, travel to a transplant center, post-transplant recovery expenses, and long-term quality-of-life expenses that government benefits do not cover.
• Housing and daily living support during periods of disease exacerbation.

Use the Special Needs Trust Funding Calculator and the Lifetime Care Cost Calculator to model the annual supplemental cost need across both a stable health scenario and a transplant scenario, then fund the SNT to the higher number.

First-party SNT: when a CF adult receives direct assets

A first-party SNT, established under 42 U.S.C. § 1396p(d)(4)(A), is used when a CF adult on SSI/Medicaid receives assets directly — through an inheritance, personal injury settlement, or other source — that would otherwise destroy benefit eligibility. Key rules: the trust must be established before age 65, must be established by a parent, grandparent, legal guardian, or court, and must contain a Medicaid payback provision at death. See the First-Party vs Third-Party SNT guide for a complete comparison of mechanics and the pooled trust alternative for adults over 65.

For CF adults specifically: if you receive an inheritance from a family member who did not have a third-party SNT set up, consult a special needs attorney immediately. There may be a brief window — varying by state — to transfer the inherited funds into a qualifying trust structure. Do not spend the money down or make gifts expecting to retain Medicaid eligibility; consult a specialist before taking any action.

ABLE account for working CF adults

ABLE accounts offer CF adults who receive SSI a beneficiary-controlled savings vehicle that doesn't count toward the SSI $2,000 resource limit (up to $100,000 in the account). Key 2026 rules:⁵

• Age eligibility: Disability onset before age 46. CF is almost always a childhood diagnosis, so virtually all CF adults qualify. The ABLE Age Adjustment Act expanded eligibility from onset before age 26 to onset before age 46, effective January 2026.
• Annual contribution limit: $20,000 from all sources in 2026.
• ABLE-to-Work: CF adults who work can contribute an additional $15,650 from earned income in 2026, above the standard $20,000 limit.
• Qualified disability expenses (QDEs) relevant to CF: medical co-pays and expenses, prescription supplements not covered by Medicaid, airway clearance vest maintenance, transportation to CF Center appointments, mental health services, nutrition supplements (many CF patients require high-calorie supplemental nutrition), adaptive sports equipment supporting lung health, and education and employment-related expenses.

For a CF adult earning a modest income while on SSI and Medicaid, the ABLE account and the Section 1619(b) protection work in combination: the ABLE account provides a savings vehicle beyond the $2,000 SSI resource limit, while 1619(b) maintains Medicaid coverage despite earned income. Together, they allow the CF adult to save meaningfully and work without losing the Medicaid coverage that makes CFTR modulator treatment economically viable.

The ABLE account complements but does not replace an SNT. The ABLE account gives the CF adult direct control over funds for everyday disability expenses; the SNT holds larger assets (inheritances, life insurance proceeds) under trustee management with the long-term perspective a larger corpus requires. Both structures should be in place for a CF adult on SSI with more than nominal assets.

Lung transplant: financial planning for the wait and beyond

Approximately 200 CF patients receive bilateral lung transplants per year in the United States. While the majority of CF patients on CFTR modulators will not require a transplant, families need to understand the financial dimensions of this path in case it becomes necessary.

Transplant costs and coverage

Lung transplant hospitalization costs — including the surgery, immediate post-operative care, and initial recovery — typically range from $200,000 to over $1,000,000 depending on complications, with a mean cost near $520,000 for the index hospitalization in recent data.⁶ Medicare covers lung transplants for SSDI recipients (after the 24-month Medicare waiting period); Medicaid covers them for Medicaid-eligible patients, though with the restriction that the transplant center must be in the patient's state of Medicaid enrollment. The Cystic Fibrosis Foundation's Compass program provides financial navigation assistance for patients evaluating or entering the transplant process.⁷

Post-transplant planning

Lung transplant recipients require lifetime immunosuppression — drugs that prevent organ rejection. Annual immunosuppressant costs run approximately $10,000–$20,000 per year, with significant variation by regimen and insurance coverage. Medicare and Medicaid cover post-transplant immunosuppressants. The SNT can cover supplemental post-transplant costs not covered by government insurance: travel to specialty transplant follow-up appointments (many CF transplant centers are regional centers), nutrition support during recovery, home health aide support, and quality-of-life expenses during the 3–6 month recovery period when employment is impossible.

SSDI during transplant evaluation and recovery

CF adults who enter the lung transplant waitlist typically have advanced disease that meets SSDI criteria — either under Listing 3.04A (FEV1 below table values), 3.04B (frequent hospitalizations), or 3.04D/F (respiratory failure or oxygen desaturation). Filing for SSDI at the time of transplant listing is appropriate and establishes the benefit stream before the surgery. The 5-month SSDI waiting period and 24-month Medicare gap should be modeled: for patients with Medicaid as their primary coverage, the gap is less of a concern. For those with employer insurance, the COBRA bridge strategy described above applies.

Retirement accounts and CF planning

Parents of CF adults often have significant retirement accounts — IRAs, 401(k)s, 403(b)s — whose beneficiary designations must be reviewed. A retirement account that names a CF adult directly as beneficiary will cause the inherited balance to count as a resource for SSI, immediately destroying SSI and Medicaid eligibility. The correct structure is to name the SNT as beneficiary, with the CF adult as the trust's beneficiary. The SECURE Act disabled EDB rules provide a lifetime stretch for retirement accounts inherited through a trust, as long as the trust meets the four-part see-through test and contains proper drafting for a disabled beneficiary. See the Retirement Accounts and Special Needs guide for the full analysis.

Priority actions for CF adults and families

1. Confirm Section 1619(b) enrollment if working and on SSI. Contact your state Medicaid agency to confirm active 1619(b) status and the current threshold for your state. Do not assume this is automatically in place — it requires ongoing SSI enrollment and periodic verification.
2. Establish a third-party SNT now, not when it's needed. Parents of CF children should establish a third-party SNT and update their wills, beneficiary designations, and any existing trusts to route assets through the SNT rather than to the CF child directly. Do not wait for a terminal prognosis; the SNT structure needs to be in place before any inheritance or gift is transferred.
3. Audit all retirement account and life insurance beneficiary designations. Replace any direct designations to a CF family member on SSI with a designation to the third-party SNT. A direct IRA designation to an SSI recipient destroys Medicaid. This step costs nothing and takes an afternoon — but must be done proactively.
4. Open an ABLE account. CF adults receiving SSI should open an ABLE account immediately. The $20,000 annual contribution limit allows meaningful savings above the SSI resource limit, and the ABLE-to-Work provision provides additional room for employed CF adults. Any state's ABLE program is available to any eligible beneficiary regardless of state of residence — choose a plan based on investment options and fees.
5. Purchase life insurance and LTD while health is stable. CF adults with well-controlled disease on Trikafta or Alyftrek should work with an independent broker to explore life insurance and own-occupation LTD coverage while coverage is obtainable. The window is open now; it may close with disease progression. Do not postpone this conversation.
6. Model the SSDI transition before it's imminent. If there is any prospect of pulmonary decline reducing work capacity in the next 5–10 years, run a financial model that includes SSDI timing, the COBRA bridge, and the Medicare gap. Identify coverage continuity options before crisis makes decision-making harder.
7. Apply for HCBS physical disability waiver now for CF adults with moderate-to-severe pulmonary impairment. Waitlists of 1–5+ years mean applying early is the only way to be in the queue when coverage becomes urgently needed.

Sources

1. Drugs.com — Trikafta Price Guide. Trikafta (elexacaftor 200mg/tezacaftor 100mg/ivacaftor 150mg plus ivacaftor 150mg), wholesale acquisition cost approximately $370,000 per year (2025–2026). Vertex patient assistance co-pay program reduces cost to $0 for commercially insured patients, subject to $20,000/year maximum savings. Actual out-of-pocket cost varies by insurance plan and assistance program eligibility.
2. Cystic Fibrosis News Today — FDA Approves Alyftrek (vanzacaftor/tezacaftor/deutivacaftor). FDA approved Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) for CF patients aged 6 and older with at least one responsive mutation, including F508del. Once-daily dosing regimen vs. Trikafta's twice-daily. Wholesale acquisition cost (WAC): $370,269/year. FDA approval granted late 2024, ahead of January 2, 2025 PDUFA date. Manufactured by Vertex Pharmaceuticals.
3. SSA — Substantial Gainful Activity, SSI Federal Benefit Rate, and 1619(b) 2026. SSI Federal Benefit Rate: $994/month for eligible individual (2026). SSI countable resource limit: $2,000 individual (unchanged). SSDI Substantial Gainful Activity: $1,690/month non-blind (2026). Section 1619(b): SSI recipients with earned income exceeding the SSI payment level may continue Medicaid if earnings are below the state's 1619(b) threshold and they remain enrolled in SSI. Thresholds vary by state and are recalculated annually based on Medicaid spending per capita. SSDI 5-month waiting period: mandatory under Social Security Act § 223(a)(1). Medicare begins 24 months after first month of SSDI entitlement. COBRA disability extension to 29 months available when SSA determines disability existed at the qualifying event date.
4. SSA Blue Book — 3.00 Respiratory Disorders (Adult), including Listing 3.04 Cystic Fibrosis. Listing 3.04 pathways: A (FEV1 ≤ Table VII-A or VII-B values by age/sex/height); B (3+ hospitalizations ≥30 days apart within 12 months); C (spontaneous pneumothorax requiring chest tube); D (respiratory failure requiring mechanical ventilation or BiPAP ≥48 hours continuous or ≥72 hours post-operatively); E (pulmonary hemorrhage requiring vascular embolization); F (SpO2 ≤89% on 2+ occasions ≥30 days apart within 12 months). CF must be documented as described in 3.00J2. RFC evaluation applies when listing criteria not met. Blue Book listings as of current SSA version.
5. ABLE National Resource Center — 2026 Contribution Limits and Eligibility. Annual ABLE contribution limit: $20,000 from all sources (2026). ABLE-to-Work: working beneficiaries may contribute additional amount up to federal poverty level for one-person household ($15,650 in 2026) from earned income. Age eligibility: disability onset before age 46, effective January 2026 (ABLE Age Adjustment Act). SSI protection: ABLE account balance up to $100,000 does not count toward SSI's $2,000 resource limit. Qualified disability expenses include transportation, health and wellness, housing, education, employment training, assistive technology, and financial management services. Any state's ABLE plan is available to any eligible beneficiary regardless of state of residence.
6. Cystic Fibrosis Foundation — Planning to Pay for a Transplant. Lung transplant hospitalization costs for CF patients range from approximately $200,000 to over $1,000,000 depending on complications and length of stay; mean cost near $520,000 for the index hospitalization based on 2013–2019 data. Medicare covers lung transplants for SSDI recipients with end-stage lung disease following the 24-month Medicare waiting period. Medicaid covers transplants but only at centers in the patient's state of Medicaid enrollment. Post-transplant immunosuppressant costs vary; covered by Medicare and Medicaid. The CF Foundation Compass program provides financial navigation assistance for patients considering or preparing for transplant.
7. Cystic Fibrosis Foundation — Patient Registry. Approximately 40,000 Americans have cystic fibrosis. Median predicted survival before CFTR modulators: approximately 30–37 years (2010 era). 2021 CF Foundation Patient Registry data: predicted median survival 53 years for existing patient population. Simulation data for patients initiating Trikafta at age 12–17: estimated median lifespan 82.5 years, approaching general population life expectancy. CF Foundation Compass program: benefits navigation support for CF patients and families, including insurance appeals, patient assistance program enrollment, and disability benefits guidance.

Rules verified against 2026 SSA, IRS, and ABLE standards. SSI FBR $994/month; SSI resource limit $2,000 (2026). SSDI SGA $1,690/month (non-blind, 2026). ABLE contribution limit $20,000/year; ABLE-to-Work additional $15,650/year; age eligibility onset before 46 (all 2026). Trikafta and Alyftrek WAC ~$370,000/year (Vertex; Alyftrek $370,269 WAC). CF patient population ~40,000 (CFF Registry). Transplant cost range from CFF and published literature. Drug pricing and insurance coverage policies change; verify current formulary status and patient assistance eligibility with CF Foundation Compass or directly with your insurance plan. This guide does not constitute financial, legal, tax, or insurance advice.